{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-25-078611","form_type":"8-K","ticker":"BNBX","cik":"0000744452","company_name":"BNB PLUS CORP.","filed_at":"2025-08-14T23:59:59+00:00","discovered_at":"2026-05-14T18:02:46.272138+00:00","generated_at":"2026-05-17T13:45:44.989643+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Applied DNA Q3 FY2025 revenue $304K, operating loss $3.7M; cash burn improves 19% sequentially","bullets":["Total revenues $304K (down 36% YoY from $473K); operating loss $3.7M vs $3.3M loss in prior year.","Adjusted EBITDA negative $3.9M; monthly net cash burn $934K, down 19% sequentially and 25% YoY.","Received follow-on LineaDNA order >$600K from IVD manufacturer; added new U.S. mRNA CDMO customer.","Cash and equivalents $4.7M at June 30, 2025, including $723K from warrant exercises.","Company closed MDx Testing Services (discontinued ops) and executed 1:15 reverse stock split in June."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-25-078611","json":"https://secwatch.observer/filing/0001104659-25-078611.json","markdown":"https://secwatch.observer/filing/0001104659-25-078611.md","text":"https://secwatch.observer/filing/0001104659-25-078611.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/744452/000110465925078611/0001104659-25-078611-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/744452/000110465925078611/tm2523531d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T13:45:44.989643+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}